Latest Articles

Publication Date
Injectable Magnetic Hydrogel Incorporated with Anti-Inflammatory Peptide for Efficient Magnetothermal Treatment of Endometriosis.

Endometriosis is a prevalent gynecological condition characterized by chronic pelvic pain, dysmenorrhea, and infertility, affecting ≈176 million women of reproductive age worldwide. Current treatments, including pharmacological and surgical interventions, are …

Published: Oct. 7, 2024, midnight
Prolactin and Hyperprolactinaemia in Endometriosis-Related Infertility: Are There Clinically Significant Connections?

Endometriosis and hyperprolactinaemia are conditions that might lead to infertility as a consequence. The aim of this article was to present the current knowledge about possible relationships between prolactin/hyperprolactinaemia and …

Published: Oct. 1, 2024, midnight
Endometriosis Beyond the Pelvis: A Case of Pancreatic Involvement.

The prevalence of dysmenorrhea, the pain while menstruating, is high. Although most cases are benign, there should be a high suspicion of other etiologies such as endometriosis with recurrent episodes. …

Published: Sept. 30, 2024, midnight
Pilot Study of IL-1 Antagonist Anakinra for Treatment of Endometriosis.

To evaluate the impact of an interleukin-1 (IL-1) antagonist anakinra (Kineret®) on endometriosis-related quality of life (QoL), pain, and inflammatory biomarkers.

Published: Sept. 27, 2024, midnight
PAK5-mediated PKM2 phosphorylation is critical for anaerobic glycolysis in endometriosis.

P21-activated kinase 5 (PAK5) belongs to the PAK-II subfamily, which is an important regulator of cell survival, adhesion, and motility. However, the functions of PAK5 in endometriosis remain unclear. Here, …

Published: Sept. 27, 2024, midnight
Effects, Doses, and Applicability of Gestrinone in Estrogen-Dependent Conditions and Post-Menopausal Women.

Gestrinone (R-2323), or ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group more commonly used as an oral, intravaginal, or subcutaneous implant for the treatment of endometriosis, contraception, and estrogen-dependent …

Published: Sept. 22, 2024, midnight
Single-cell analysis identifies distinct macrophage phenotypes associated with prodisease and proresolving functions in the endometriotic niche.

Endometriosis negatively impacts the health-related quality of life of 190 million women worldwide. Novel advances in nonhormonal treatments for this debilitating condition are desperately needed. Macrophages play a vital role …

Published: Sept. 10, 2024, midnight
Breaking the silence: The role of extracellular vesicles in unraveling the diagnosis and treatment of endometriosis.

Cell-to-cell communication is believed to be facilitated by membrane-bound vesicles called extracellular vesicles (EVs), which are released by cells. Protein, lipids, and nucleic acids are major cargo of EVs and …

Published: Dec. 4, 2023, midnight
Safety, Pharmacokinetics, and Pharmacodynamics of SHR7280, a Non-peptide GnRH Antagonist in Premenopausal Women with Endometriosis: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.

Oral gonadotropin-releasing hormone (GnRH) antagonists are promising agents in the treatment of endometriosis-related pain. Here we assessed the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SHR7280, an oral non-peptide GnRH …

Published: Oct. 14, 2023, midnight
Update on the management of endometriosis-associated pain in France.

The French National College of Obstetricians and Gynecologists (CNGOF) published guidelines for managing endometriosis-associated pain in 2018. Given the development of new pharmacological therapies and a review that was published …

Published: Sept. 3, 2023, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!